Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C3805119
Disease: Parkinson's disease psychosis
Parkinson's disease psychosis
0.040 Biomarker disease BEFREE One such possible agent is the non-dopaminergic antipsychotic pimavanserin, an inverse agonist of serotonin 5-HT2A receptors which was recently approved for the hallucinations and delusions of Parkinson's Disease Psychosis. 30837203 2019
CUI: C3805119
Disease: Parkinson's disease psychosis
Parkinson's disease psychosis
0.040 Biomarker disease BEFREE Pimavanserin, a 5-HT2A inverse agonist approved to treat Parkinson's disease psychosis, may improve sleep quality in patients with Parkinson's disease experiencing sleep disturbances. 30303817 2018
CUI: C3805119
Disease: Parkinson's disease psychosis
Parkinson's disease psychosis
0.040 Biomarker disease BEFREE Our aim was to describe the efficacy and tolerability of pimavanserin, a highly selective serotonin 5-HT2A receptor inverse agonist/antagonist indicated for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis (PDP), using the metrics of number needed to treat (NNT) and number needed to harm (NNH). 29098976 2018
CUI: C3805119
Disease: Parkinson's disease psychosis
Parkinson's disease psychosis
0.040 Biomarker disease BEFREE Pimavanserin, a 5-HT2A inverse agonist, was commercially released in the United States in April 2016 for the treatment of Parkinson disease psychosis. 28622212 2018